Zacks • 6 days agoZacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies
Zacks.com featured highlights: Ets, Incyte, Abercrombie & Fitch, Vertex Pharmaceuticals and Bottomline Technologies
Zacks • 10 days ago
Inflated price of the toxic stocks can be ascribed to either an irrational exuberance associated with them or some serious fundamental lacuna.
TheStreet.com • 23 days ago
Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday.
Capital Cube • 24 days agoVertex Pharmaceuticals, Inc. :VRTX-US: Earnings Analysis: Q4, 2016 By the Numbers : January 26, 2017
Categories: Yahoo Finance Get free summary analysis Vertex Pharmaceuticals, Inc. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of Vertex Pharmaceuticals, Inc. – Johnson & Johnson (JNJ-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 458.71 million, Net Earnings of USD 32.95 ... Read more (Read more...)
Zacks • 24 days ago
Vertex Pharmaceuticals Inc. (VRTX) reported fourth-quarter 2016 earnings of 11 cents per share (including the impact of stock-based compensation expenses). The Zacks Consensus Estimate was of a loss of 1 cent per share.
Associated Press • 25 days ago
Vertex Pharmaceuticals Inc. (VRTX) on Wednesday reported fourth-quarter net income of $32.9 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Boston-based company ...
VRTX : Summary for Vertex Pharmaceuticals Incorpor - Yahoo Finance
Vertex Pharmaceuticals Incorporated (VRTX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||86.07 x 100|
|Ask||91.50 x 600|
|Day's Range||86.90 - 88.98|
|52 Week Range||71.46 - 103.73|
|PE Ratio (TTM)||-77.89|
|Earnings Date||Apr 25, 2017 - May 1, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||98.95|